516 related articles for article (PubMed ID: 26218032)
1. Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
Nolan B; Mahlangu J; Perry D; Young G; Liesner R; Konkle B; Rangarajan S; Brown S; Hanabusa H; Pasi KJ; Pabinger I; Jackson S; Cristiano LM; Li X; Pierce GF; Allen G
Haemophilia; 2016 Jan; 22(1):72-80. PubMed ID: 26218032
[TBL] [Abstract][Full Text] [Related]
2. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.
Nolan B; Mahlangu J; Pabinger I; Young G; Konkle BA; Barnes C; Nogami K; Santagostino E; Pasi KJ; Khoo L; Winding B; Yuan H; Fruebis J; Rudin D; Oldenburg J
Haemophilia; 2020 May; 26(3):494-502. PubMed ID: 32227570
[TBL] [Abstract][Full Text] [Related]
3. Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A.
Shapiro AD; Mahlangu JN; Perry D; Pasi J; Quon DV; Chowdary P; Tsao E; Li S; Innes A; Pierce GF; Allen GA
Haemophilia; 2017 May; 23(3):392-399. PubMed ID: 28220631
[TBL] [Abstract][Full Text] [Related]
4. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
Haemophilia; 2017 May; 23(3):408-416. PubMed ID: 28233383
[TBL] [Abstract][Full Text] [Related]
5. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
Young G; Mahlangu J; Kulkarni R; Nolan B; Liesner R; Pasi J; Barnes C; Neelakantan S; Gambino G; Cristiano LM; Pierce GF; Allen G
J Thromb Haemost; 2015 Jun; 13(6):967-77. PubMed ID: 25912075
[TBL] [Abstract][Full Text] [Related]
6. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A.
Mahlangu JN; Ragni M; Gupta N; Rangarajan S; Klamroth R; Oldenburg J; Nogami K; Young G; Cristiano LM; Dong Y; Allen G; Pierce GF; Robinson B
Thromb Haemost; 2016 Jul; 116(1):1-8. PubMed ID: 26962852
[TBL] [Abstract][Full Text] [Related]
7. Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein.
Oldenburg J; Kulkarni R; Srivastava A; Mahlangu JN; Blanchette VS; Tsao E; Winding B; Dumont J; Jain N
Haemophilia; 2018 Jan; 24(1):77-84. PubMed ID: 29082639
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.
Pasi KJ; Fischer K; Ragni M; Nolan B; Perry DJ; Kulkarni R; Ozelo M; Mahlangu J; Shapiro AD; Baker RI; Bennett CM; Barnes C; Oldenburg J; Matsushita T; Yuan H; Ramirez-Santiago A; Pierce GF; Allen G; Mei B
Thromb Haemost; 2017 Feb; 117(3):508-518. PubMed ID: 28004057
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.
Carcao M; Shapiro A; Staber JM; Hwang N; Druzgal C; Lieuw K; Belletrutti M; Thornburg CD; Ahuja SP; Morales-Arias J; Dumont J; Miyasato G; Tsao E; Jain N; Pipe SW
Haemophilia; 2018 Mar; 24(2):245-252. PubMed ID: 29436077
[TBL] [Abstract][Full Text] [Related]
11. Design of a prospective observational study on the effectiveness and real-world usage of recombinant factor VIII Fc (rFVIIIFc) compared with conventional products in haemophilia A: the A-SURE study.
Oldenburg J; Hay CRM; Jiménez-Yuste V; Peyvandi F; Schved JF; Szamosi J; Winding B; Lethagen S
BMJ Open; 2019 May; 9(5):e028012. PubMed ID: 31152037
[TBL] [Abstract][Full Text] [Related]
12. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.
Mahlangu J; Powell JS; Ragni MV; Chowdary P; Josephson NC; Pabinger I; Hanabusa H; Gupta N; Kulkarni R; Fogarty P; Perry D; Shapiro A; Pasi KJ; Apte S; Nestorov I; Jiang H; Li S; Neelakantan S; Cristiano LM; Goyal J; Sommer JM; Dumont JA; Dodd N; Nugent K; Vigliani G; Luk A; Brennan A; Pierce GF;
Blood; 2014 Jan; 123(3):317-25. PubMed ID: 24227821
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B-YOND extension study.
Pasi KJ; Fischer K; Ragni M; Kulkarni R; Ozelo MC; Mahlangu J; Shapiro A; P'Ng S; Chambost H; Nolan B; Bennett C; Matsushita T; Winding B; Fruebis J; Yuan H; Rudin D; Oldenburg J
Haemophilia; 2020 Nov; 26(6):e262-e271. PubMed ID: 32497409
[TBL] [Abstract][Full Text] [Related]
15. Efmoroctocog Alfa: A Review in Haemophilia A.
Frampton JE
Drugs; 2016 Sep; 76(13):1281-1291. PubMed ID: 27487799
[TBL] [Abstract][Full Text] [Related]
16. Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults.
Konkle BA; Oldenburg J; Pasi J; Kulkarni R; Nolan B; Mahlangu J; Young G; Brown SA; Pabinger I; Shapiro A; Négrier C; Blanchette V; Ragni MV; Dumont J; Lethagen S
Res Pract Thromb Haemost; 2023 Aug; 7(6):102180. PubMed ID: 37753224
[TBL] [Abstract][Full Text] [Related]
17. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.
Powell JS; Josephson NC; Quon D; Ragni MV; Cheng G; Li E; Jiang H; Li L; Dumont JA; Goyal J; Zhang X; Sommer J; McCue J; Barbetti M; Luk A; Pierce GF
Blood; 2012 Mar; 119(13):3031-7. PubMed ID: 22223821
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor VIII Fc for the treatment of haemophilia A.
Hermans C; Mancuso ME; Nolan B; Pasi KJ
Eur J Haematol; 2021 Jun; 106(6):745-761. PubMed ID: 33650192
[TBL] [Abstract][Full Text] [Related]
19. Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect Comparison.
Hakimi Z; Santagostino E; Postma MJ; Nazir J
Adv Ther; 2021 Feb; 38(2):1263-1274. PubMed ID: 33377987
[TBL] [Abstract][Full Text] [Related]
20. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results.
Königs C; Ozelo MC; Dunn A; Kulkarni R; Nolan B; Brown SA; Schiavulli M; Gunawardena S; Mukhopadhyay S; Jayawardene D; Winding B; Carcao M
Blood; 2022 Jun; 139(26):3699-3707. PubMed ID: 35421219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
